Expertise in
36
conditions

Dr. Alberto Bessudo

Hematology | Oncology
California Cancer Associates For Research And Excellence, Inc
326 Santa Fe Dr Ste 105, 
Encinitas, CA 
Offers Telehealth
Expertise in
36
conditions
California Cancer Associates For Research And Excellence, Inc
326 Santa Fe Dr Ste 105, 
Encinitas, CA 

Overview

Alberto Bessudo is a Hematologist and an Oncologist practicing medicine in Encinitas, California.

Dr. Bessudo is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Bone Tumor, Multiple Myeloma, Colorectal Cancer, and Vitamin B12 Deficiency.

He is actively involved in clinical research, co-authoring 25 peer reviewed articles and participating in 10 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Scripps Memorial Hospital - Encinitas
Scripps Memorial Hospital La Jolla
Tri-City Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

California Cancer Associates For Research And Excellence, Inc
326 Santa Fe Dr Ste 105, Encinitas, CA 92024
Other Locations
Office
326 Santa Fe Dr Ste 105, Encinitas, CA 92024
California Cancer Associates for Research and Excellence Inc
838 Nordahl Rd Ste 300, San Marcos, CA 92069

Additional Areas of Focus

Dr. Bessudo has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
Enrollment Status: Active_not_recruiting
Publish Date: July 14, 2026
Intervention Type: Drug
Study Drug: Tepotinib
Study Phase: Phase 2
An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors
An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 26, 2026
Intervention Type: Drug, Biological
Study Phase: Phase 2
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of Vilastobart (XTX101) Monotherapy and Vilastobart (XTX101) and Atezolizumab Combination Therapy in Patients With Advanced Solid Tumors
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of Vilastobart (XTX101) Monotherapy and Vilastobart (XTX101) and Atezolizumab Combination Therapy in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: June 16, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer
Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer
Enrollment Status: Completed
Publish Date: November 25, 2025
Intervention Type: Drug
Study Drugs: Niraparib, TSR-042 Anti-PD-1 Antibody, Bevacizumab, TSR-022 Anti-TIM-3 Antibody, Carboplatin, Pemetrexed, Nab-Paclitaxel
Study Phase: Phase 1
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients With Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations
A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients With Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations
Enrollment Status: Active_not_recruiting
Publish Date: September 24, 2025
Intervention Type: Drug
Study Drug: HBI-2376
Study Phase: Phase 1
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
Enrollment Status: Completed
Publish Date: October 10, 2024
Intervention Type: Drug
Study Drugs: LAE001, Prednisone, Afuresertib
Study Phase: Phase 1/Phase 2
An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 25, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination With Pomalidomide, Carfilzomib and Dexamethasone Among High Risk Relapsed/ Refractory Multiple Myeloma Patients
A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination With Pomalidomide, Carfilzomib and Dexamethasone Among High Risk Relapsed/ Refractory Multiple Myeloma Patients
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug
Study Drugs: Elotuzumab, Pomalidomide, Carfilzomib, Dexamethasone
Study Phase: Phase 2
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: June 02, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

25 Total Publications

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer.
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer.
Journal: Clinical colorectal cancer
Published: January 10, 2024
Similar Doctors
Expertise in
24
conditions
Dr. James I. Geller
Hematology | Oncology
Expertise in
24
conditions
Dr. James I. Geller
Hematology | Oncology
Referral may be required

Rady Children's Hospital San Diego

3020 Childrens Way, 
San Diego, CA 
 (18.9 miles away)
858-966-5811
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Geller is a Hematologist and an Oncologist practicing medicine in San Diego, California. Dr. Geller is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Wilms Tumor, Hepatoblastoma, Renal Cell Carcinoma (RCC), Nephrectomy, and Bone Marrow Aspiration. Dr. Geller is currently accepting new patients.

Expertise in
10
conditions
Dr. Courtney D. Thornburg
Hematology | Oncology
Expertise in
10
conditions
Dr. Courtney D. Thornburg
Hematology | Oncology
Referral may be required

Office

3010 Childrens Way, 
San Diego, CA 
 (19.0 miles away)
858-966-8035
Languages Spoken:
English
See accepted insurances

Courtney Thornburg is a Hematologist and an Oncologist practicing medicine in San Diego, California. Dr. Thornburg is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Hemophilia A, Blood Clots, Sickle Cell Disease, Hemolytic Anemia, and Splenectomy.

Expertise in
23
conditions
Dr. Gregory Daniels
Hematology | Oncology
Expertise in
23
conditions
Dr. Gregory Daniels
Hematology | Oncology
Referral may be required

Ucsd Health Moores Cancer Center

3855 Health Sciences Dr, 
La Jolla, CA 
 (12.5 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gregory Daniels is a Hematologist and an Oncologist practicing medicine in La Jolla, California. Dr. Daniels is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Melanoma, Follicular Thyroid Cancer, Thyroid Cancer, Oral Squamous Cell Carcinoma, and Tissue Biopsy.

Frequently Asked Questions about Dr. Alberto Bessudo

How do I make an appointment with Dr. Alberto Bessudo?

You can book an appointment with Dr. Alberto Bessudo by calling their office at 858-552-1410. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Alberto Bessudo a top-rated expert for Bone Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Alberto Bessudo is classified as an Distinguished expert for Bone Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Alberto Bessudo specialize in?

While Dr. Alberto Bessudo is a Hematology, they have specific expertise in Bone Tumor, Multiple Myeloma, and Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Alberto Bessudo participate in research or clinical trials?

Yes. Dr. Alberto Bessudo has published 25 articles and abstracts on conditions like Bone Tumor. You can view a list of Dr. Alberto Bessudo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Alberto Bessudo accept my insurance?

Dr. Alberto Bessudo accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 858-552-1410 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bessudo's expertise for a condition
ConditionClose
    View All 30 Advanced Conditions
    View All 113 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile